1-11 of 11
Woonbok Chung
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genetic Determinants of Response to Guadecitabine (SGI-110) in AML

Patricia L. Kropf, MD, Woonbok Chung, PhD, Andrew D. Kelly, BA, Hagop M. Kantarjian, MD, Gail J. Roboz, Karen W.L. Yee, MD, Pietro Taverna, PhD, Sue Naim, Mohammad Azab, MD, Jaroslav Jelinek, MD PhD, Jean-Pierre J. Issa, MD
Journal: Blood
Blood (2016) 128 (22): 1680.
https://doi.org/10.1182/blood.V128.22.1680.1680
Published: 2016
Journal Articles

Improved Survival for MDS/CMML Patients Treated with the Combination of Decitabine (DAC) and Arsenic Trioxide (ATO) in a Phase II Adaptive Three Arm Randomization Study: DAC Alone Vs. DAC +/- Carboplatin or ATO

Patricia L. Kropf, MD, Raji Shameem, MD, Philip A. Pancari, MD, Henry Fung, MD, Lianchun Xiao, PhD, Xuelin Huang, PhD, Woonbok Chung, PhD, Hagop M. Kantarjian, MD, Jean-Pierre J. Issa, MD
Journal: Blood
Blood (2016) 128 (22): 3170.
https://doi.org/10.1182/blood.V128.22.3170.3170
Published: 2016
Journal Articles

Multivariate Analysis Identifies Significant Correlations Between Baseline Biomarkers, DNA Demethylation and Clinical Responses in 122 Patients Treated in a Phase 1/2, Study of Guadecitabine (SGI-110), in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia (r/r AML)

Srikanth Gottipati, PhD, Shashank Rohatagi, PhD, Woonbok Chung, PhD, Pietro Taverna, PhD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD, Patricia L. Kropf, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2015) 126 (23): 2594.
https://doi.org/10.1182/blood.V126.23.2594.2594
Published: 2015
Journal Articles

First Clinical Results of a Randomized Phase 2 Dose-Response Study of SGI-110, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate (Int) or High Risk (HR) Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Guillermo Garcia-Manero, MD, Ellen K. Ritchie, MD, Katherine Walsh, MD, Michael Savona, MD, Patricia Kropf, MD, Casey O'Connell, MD, Raoul Tibes, MD, Naval G. Daver, MD, Elias Jabbour, MD, Scott Lunin, MD, Todd L. Rosenblat, MD, Karen Yee, MD, Wendy Stock, MD, Elizabeth A. Griffiths, MD, Joseph R Mace, MD, Nikolai A. Podoltsev, MDPhD, Jesus G. Berdeja, MD, Jean-Pierre Issa, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2014) 124 (21): 529.
https://doi.org/10.1182/blood.V124.21.529.529
Published: 2014
Journal Articles

DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML

Gail J. Roboz, MD, Jean-Pierre Issa, MD, David Rizzieri, MD, Wendy Stock, MD, Casey O'Connell, MD, Karen Yee, MD, Raoul Tibes, MD, Elizabeth A. Griffiths, MD, Katherine Walsh, MD, Eric J. Feldman, MD, Ellen Ritchie, MD, Arati V. Rao, MD, Richard A. Larson, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Jorge E. Cortes, MD, Aaron Schimmer, PhD, MD, Ruben A. Mesa, MD, William Blum, MD, Woonbok Chung, PhD, Sue Naim, Pietro Taverna, PhD, Yong Hao, PhD, Gavin Choy, PharmD, Mohammad Azab, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2013) 122 (21): 1548.
https://doi.org/10.1182/blood.V122.21.1548.1548
Published: 2013
Journal Articles

Determinants Of Demethylation and Clinical Response In AML Patients Treated With SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA) In a Phase 1 Study

Woonbok Chung, PhD, Pietro Taverna, PhD, John F Lyons, PhD, Yong Hao, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD, Patricia Kropf, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 1442.
https://doi.org/10.1182/blood.V122.21.1442.1442
Published: 2013
Journal Articles

First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML)

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Karen Yee, MD, Patricia Kropf, MD, Casey O'Connell, MD, Wendy Stock, MD, Raoul Tibes, MD, PhD, David Rizzieri, MD, Katherine Walsh, MD, Elizabeth A. Griffiths, MD, Gail J. Roboz, MD, Michael Savona, MD, Thomas Ervin, MD, Nikolai A. Podoltsev, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, William G. Wierda, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Joseph M. Brandwein, MD, Olatoyosi Odenike, MBBS, Eric J. Feldman, MD, Woonbok Chung, PhD, Sue Naim, Gavin Choy, PharmD, Pietro Taverna, PhD, Yong Hao, PhD, George Dimitrov, MD, Mohammad Azab, MD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2013) 122 (21): 497.
https://doi.org/10.1182/blood.V122.21.497.497
Published: 2013
Journal Articles

Results From the Dose Escalation Phase of a Randomized Phase 1–2 First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML

Hagop M. Kantarjian, MD, Gail J. Roboz, MD, David A. Rizzieri, MD, Wendy Stock, MD, Casey L. O'Connell, MD, Elizabeth A Griffiths, MD, Karen Yee, MD, Raoul Tibes, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Katherine Walsh, MD, Eric Feldman, MD, Ellen Ritchie, MD, Arati Rao, MD, Carlos Decastro, MD, Aaron D. Schimmer, MD, Ruben A. Mesa, Ibrahim Syed, MBBS, Gavin Choy, PharmD, Aram Oganesian, PhD, Pietro Taverna, PhD, Mohammad Azab, MD, Woonbok Chung, PhD, Jean-Pierre Issa, MD
Journal: Blood
Blood (2012) 120 (21): 414.
https://doi.org/10.1182/blood.V120.21.414.414
Published: 2012
Journal Articles

Microrna 124 and Its Role in Response to Epigenetic Therapy in Patients with Acute Mylogenous Leukemia and Myelodysplastic Syndrome

Ryan J Castoro, Mhair Dekmezian, Amanda J Saraf, Yoshiyuki Watanabe, Woonbok Chung, Samih El Adhab, Jaroslav Jelinek, Jean-Pierre Issa, MD
Journal: Blood
Blood (2008) 112 (11): 598.
https://doi.org/10.1182/blood.V112.11.598.598
Published: 2008
Journal Articles

Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse

Heike Kroeger, Jaroslav Jelinek, Marcos R. H. Estécio, Rong He, Kimie Kondo, Woonbok Chung, Li Zhang, Lanlan Shen, Hagop M. Kantarjian, Carlos E. Bueso-Ramos, Jean-Pierre J. Issa
Journal: Blood
Blood (2008) 112 (4): 1366–1373.
https://doi.org/10.1182/blood-2007-11-126227
Published: 2008
Includes: Supplemental data
Journal Articles

Aberrant DNA Methylation in CML Is Associated with Disease Progression and Resistance to Imatinib Mesylate.

Jaroslav Jelinek, MD, PhD, Vazganush Gharibyan, Yasuhiro Oki, MD, Woonbok Chung, PhD, Lanlan Shen, MD PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Jean-Pierre J. Issa, MD
Journal: Blood
Blood (2006) 108 (11): 2192.
https://doi.org/10.1182/blood.V108.11.2192.2192
Published: 2006